Neurocrine Biosciences (NASDAQ:NBIX) had its price target hoisted by Stifel Nicolaus from $137.00 to $142.00 in a research note issued to investors on Thursday, September 20th. The brokerage currently has a buy rating on the stock.
Other analysts have also recently issued research reports about the company. Needham & Company LLC set a $125.00 price target on Neurocrine Biosciences and gave the stock a buy rating in a research report on Wednesday, August 1st. HC Wainwright restated a buy rating and issued a $162.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday, August 1st. Oppenheimer set a $128.00 price target on Neurocrine Biosciences and gave the stock a buy rating in a research report on Tuesday, July 31st. Jefferies Financial Group upped their price target on Neurocrine Biosciences to $124.00 and gave the stock a buy rating in a research report on Monday, July 30th. Finally, BidaskClub upgraded Neurocrine Biosciences from a hold rating to a buy rating in a research report on Friday, July 27th. One equities research analyst has rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $122.22.
NBIX stock traded up $3.42 during trading on Thursday, reaching $111.48. The stock had a trading volume of 691,320 shares, compared to its average volume of 781,505. The company has a debt-to-equity ratio of 1.00, a quick ratio of 9.19 and a current ratio of 9.19. The company has a market cap of $11.12 billion, a price-to-earnings ratio of -68.81, a P/E/G ratio of 38.11 and a beta of 0.55. Neurocrine Biosciences has a 52 week low of $57.71 and a 52 week high of $126.98.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Tuesday, July 31st. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.11. The business had revenue of $96.90 million during the quarter, compared to analysts’ expectations of $84.11 million. Neurocrine Biosciences had a negative return on equity of 14.22% and a negative net margin of 16.07%. The business’s quarterly revenue was up 1428.4% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.68) earnings per share. Equities analysts predict that Neurocrine Biosciences will post 0.15 earnings per share for the current year.
In other Neurocrine Biosciences news, insider Dimitri E. Grigoriadis sold 23,022 shares of the firm’s stock in a transaction that occurred on Wednesday, August 1st. The stock was sold at an average price of $110.00, for a total transaction of $2,532,420.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.30% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NBIX. Schwab Charles Investment Management Inc. lifted its stake in shares of Neurocrine Biosciences by 7.3% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 439,518 shares of the company’s stock valued at $36,450,000 after purchasing an additional 29,996 shares during the last quarter. Aperio Group LLC lifted its stake in shares of Neurocrine Biosciences by 8.3% in the 1st quarter. Aperio Group LLC now owns 27,047 shares of the company’s stock valued at $2,243,000 after purchasing an additional 2,080 shares during the last quarter. Rockefeller Capital Management L.P. bought a new stake in shares of Neurocrine Biosciences in the 1st quarter valued at approximately $305,000. Northern Trust Corp lifted its stake in shares of Neurocrine Biosciences by 3.3% in the 1st quarter. Northern Trust Corp now owns 483,801 shares of the company’s stock valued at $40,122,000 after purchasing an additional 15,395 shares during the last quarter. Finally, BlackRock Inc. lifted its stake in shares of Neurocrine Biosciences by 2.8% in the 1st quarter. BlackRock Inc. now owns 4,908,495 shares of the company’s stock valued at $407,061,000 after purchasing an additional 132,749 shares during the last quarter.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C.
Further Reading: Google Finance
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.